{"id":"acediasulfone","rwe":[{"pmid":"17474511","year":"2007","title":"Column and thin-layer chromatographic methods for the simultaneous determination of acediasulfone in the presence of cinchocaine, and cefuroxime in the presence of its hydrolytic degradation products.","finding":"","journal":"Journal of AOAC International","studyType":"Clinical Study"}],"tags":[{"label":"acediasulfone","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["acediasulfone"],"offLabel":[],"synonyms":["acediasulfone"],"timeline":[],"aiSummary":"Acediasulfone is a small molecule drug in the acediasulfone class, but its original developer and current owner are unknown. Its target and approved indications are also not specified. The commercial status of acediasulfone is unclear, and it is unknown whether it is patented or available as a generic medication. Further information on its pharmacokinetic properties, such as half-life and bioavailability, is also lacking. As a result, key safety considerations and potential side effects are not well established.","ecosystem":[],"mechanism":{"target":"6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase, Aldose reductase, Dihydropteroate synthetase, putative","modality":"Small Molecule","drugClass":"acediasulfone","explanation":"Imagine your body's cells have locks on them, and acediasulfone is a key that fits into those locks. When it binds, it can either unlock or block the normal functioning of the cell, depending on the specific target. This can help to treat certain diseases by either activating or inhibiting the cell's normal processes.","oneSentence":"Acediasulfone works by binding to a specific target, but the exact mechanism is not well understood.","technicalDetail":"Acediasulfone is a small molecule that interacts with a specific protein or receptor, potentially altering its activity or expression. The exact molecular details of this interaction are not well established, but it is thought to involve specific binding sites and conformational changes in the target protein."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/44","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ACEDIASULFONE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:21:48.240416","biosimilars":[],"competitors":[{"drugName":"indomethacin","drugSlug":"indomethacin","fdaApproval":"1965-06-10","patentExpiry":"Apr 23, 2030","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"valproic acid","drugSlug":"valproic-acid","fdaApproval":"1978-02-28","genericCount":14,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"acediasulfone","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"indomethacin","brandName":"indomethacin","genericName":"indomethacin","approvalYear":"1965","relationship":"same-target"},{"drugId":"valproic-acid","brandName":"valproic acid","genericName":"valproic acid","approvalYear":"1978","relationship":"same-target"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"30YP2YHH8W","UMLSCUI":"C1958507","ChEMBL_ID":"CHEMBL48396","DRUGBANK_ID":"DB08926","PUBCHEM_CID":"66451","MESH_SUPPLEMENTAL_RECORD_UI":"C521214"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":1,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2007 Mar-Apr","pmid":"17474511","title":"Column and thin-layer chromatographic methods for the simultaneous determination of acediasulfone in the presence of cinchocaine, and cefuroxime in the presence of its hydrolytic degradation products.","journal":"Journal of AOAC International"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"ACEDIASULFONE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}